Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM001 in Advanced Solid Tumors
NCT06475937Phase 1Active, not recruiting
- Sponsor
- Xadcera Biopharmaceutical
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of DM001 in solid tumor, breast cancer, non-small cell lung cancer (NSCLC) and 3 more, sponsored by Xadcera Biopharmaceutical. Primary endpoints: Dose-limiting Toxicities at 12 months and Maximum tolerated dose at 12 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
DM001
03
Conditions
solid tumorbreast cancernon-small cell lung cancer (NSCLC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06475937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475937.